AC   CVCL_0467
AS   CVCL_6475
SY   NPA-87; NPA'87; NPA 87; NPA87; NPA87-1; UCLA NPA-87-1; UCLA NPA871
DR   BTO; BTO:0004771
DR   MCCL; MCC:0000365
DR   BioSample; SAMN03151835
DR   cancercelllines; CVCL_0467
DR   Cosmic; 685605
DR   Cosmic; 686727
DR   Cosmic; 849968
DR   Cosmic; 886547
DR   Cosmic; 918183
DR   Cosmic; 928835
DR   Cosmic; 931239
DR   Cosmic; 990533
DR   Cosmic; 1005456
DR   Cosmic; 1021384
DR   Cosmic; 1071908
DR   Cosmic; 1094772
DR   Cosmic; 1132596
DR   Cosmic; 1152122
DR   Cosmic; 1155264
DR   Cosmic; 1155328
DR   Cosmic; 1161613
DR   Cosmic; 1162848
DR   Cosmic; 1176608
DR   Cosmic; 1699416
DR   IARC_TP53; 2129
DR   TOKU-E; 4068
DR   Wikidata; Q54930968
RX   PubMed=2551628;
RX   PubMed=8423216;
RX   PubMed=8871538;
RX   PubMed=11439348;
RX   PubMed=14522906;
RX   PubMed=15980887;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
CC   Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland papillary carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00246.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=8423216; PubMed=14522906).
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): PubMed=18713817; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 9,13
ST   D18S51: 13,17
ST   D21S11: 30
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 21
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1395 ! M14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 31
RX   PubMed=2551628; DOI=10.1210/endo-125-4-1783;
RA   Pang X.-P., Hershman J.M., Chung M., Pekary A.E.;
RT   "Characterization of tumor necrosis factor-alpha receptors in human
RT   and rat thyroid cells and regulation of the receptors by
RT   thyrotropin.";
RL   Endocrinology 125:1783-1788(1989).
RX   PubMed=8423216; DOI=10.1172/JCI116168;
RA   Fagin J.A., Matsuo K., Karmakar A., Chen D.-L., Tang S.-H.,
RA   Koeffler H.P.;
RT   "High prevalence of mutations of the p53 gene in poorly differentiated
RT   human thyroid carcinomas.";
RL   J. Clin. Invest. 91:179-184(1993).
RX   PubMed=8871538; DOI=10.1007/BF00128960;
RA   Boghaert E.R., Ain K.B., Taylor K.D., Greenberg V.L., Fowler C.,
RA   Zimmer S.G.;
RT   "Quantitative and qualitative differences in growth, invasion and lung
RT   colonization of an anaplastic and a papillary human thyroid cancer
RT   cell line in vitro and in vivo.";
RL   Clin. Exp. Metastasis 14:440-450(1996).
RX   PubMed=11439348; DOI=10.1038/sj.onc.1204531;
RA   Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.;
RT   "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile
RT   response to hepatocyte growth factor.";
RL   Oncogene 20:3845-3856(2001).
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
RX   PubMed=15980887; DOI=10.1038/labinvest.3700306;
RA   Nakamura N., Carney J.A., Jin L., Kajita S., Pallares J., Zhang H.-Y.,
RA   Qian X., Sebo T.J., Erickson L.A., Lloyd R.V.;
RT   "RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid
RT   tumors.";
RL   Lab. Invest. 85:1065-1075(2005).
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).